William Duke Biography and Net Worth

Chief Financial Officer of Invivyd

William (Bill) Duke, Jr., M.B.A. has served as our Chief Financial Officer since September 2023. He brings more than 25 years of finance, accounting, and operations experience, including over a decade of senior leadership experience in the biotechnology industry. Prior to joining Invivyd, Bill served as the Chief Financial Officer of Apexigen, Inc. where he was responsible for all areas of finance and accounting and helped guide the company through its sale to Pyxis Oncology, Inc. Before Apexigen, he was Chief Financial Officer of Kaleido Biosciences, Inc., where he led the successful completion of multiple financings. Prior to Kaleido Biosciences, he was Chief Financial Officer of Pulmatrix, Inc., where he helped negotiate the company’s first product partnership and led the successful completion of several public offerings. Prior to that, he held senior financial leadership roles at Valeritas, Inc. and Genzyme Corporation, where he helped in the sale of the company to Sanofi. Bill is a certified public accountant and holds a B.S. in Business Administration from Stonehill College and an M.B.A. from Bentley College.

What is William E. Duke's net worth?: The estimated net worth of William E. Duke is at least $183.66 thousand as of February 18th, 2026. Mr. Duke owns 107,717 shares of Invivyd stock worth more than $183,657 as of April 10th. This net worth estimate does not reflect any other investments that Mr. Duke may own. Learn More about William E. Duke's net worth.
How do I contact William E. Duke?: The corporate mailing address for Mr. Duke and other Invivyd executives is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. Invivyd can also be reached via phone at 781-819-0080 and via email at [email protected]. Learn More on William E. Duke's contact information.
Has William E. Duke been buying or selling shares of Invivyd?: William E. Duke has not been actively trading shares of Invivyd during the past quarter. Most recently, William E. Duke sold 20,964 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a transaction totalling $33,123.12. Following the completion of the sale, the chief financial officer now directly owns 107,717 shares of the company's stock, valued at $170,192.86. Learn More on William E. Duke's trading history.
Who are Invivyd's active insiders?: Invivyd's insider roster includes Robert Allen, III (Chief Scientific Officer), William Duke (Chief Financial Officer), Julie Green (Chief Human Resources Officer), and Timothy Lee (Chief Commercial Officer). Learn More on Invivyd's active insiders.
Are insiders buying or selling shares of Invivyd?: In the last twelve months, Invivyd insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $125,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 504,826 shares worth more than $521,748.82. The most recent insider tranaction occured on February, 18th when insider Robert D Allen III sold 19,392 shares worth more than $30,639.36. Insiders at Invivyd own 25.4% of the company. Learn More about insider trades at Invivyd.
Information on this page was last updated on 2/18/2026.

William E. Duke Insider Trading History at Invivyd

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2026	Sell	20,964	$1.58	$33,123.12	107,717
2/17/2026	Sell	19,663	$1.54	$30,281.02	128,681
8/19/2025	Sell	29,643	$0.57	$16,896.51	49,344
8/18/2025	Sell	20,013	$0.65	$13,008.45	78,987

William E. Duke Buying and Selling Activity at Invivyd

Invivyd Company Overview

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $1.77

$1.62

$1.77

50 Day Range

MA: $1.59

$1.19

$1.90

2 Week Range

Now: $1.77

$0.46

$3.07

Volume

8,572,829 shs

Average Volume

3,074,031 shs

Market Capitalization

$499.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73